[Close]
This page was created by volunteers like you!
Help us make it even better. To learn more about contributing to MEpedia, click here.
Join the movement
Visit #MEAction to find support or take action. Donate today to help us improve and expand this project.
Congratulations!
MEpedia has got over 30 million views as of August 2022!

Arbaclofen

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Arbaclofen or arbaclofen placarbil or ARBaclofen or Ontinua ER is an investigational drug related to baclofen, it is being investigated for muscle spasticity (muscle spasms).[1] Arbaclofen is a GABA-B agonist, and is being investigated as a muscle relexant for multiple sclerosis.[2]

Theory[edit | edit source]

Evidence[edit | edit source]

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Costs and availability[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. ↑ https://www.rxlist.com/consumer_arbaclofen/drugs-condition.htm
  2. ↑ "Ontinua ER (arbaclofen) dosing, indications, interactions, adverse effects, and more". Medscape. Retrieved January 16, 2022.

A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.[1][2]

agonist A chemical that binds to the receptor and stimulates it's function, e.g., morphine is an opioid agonist that binds to the opioid receptor, reducing pain. The opposite of an antagonist.

Retrieved from "https://me-pedia.org/w/index.php?title=Arbaclofen&oldid=232670"